GlassScriptPhysician profile
Christopher R Speer
NPI 1346263837
$837.05
in general payments reported to CMS, 2019-2025
23 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $53.66 · 2021: $183 · 2023: $144 · 2024: $206 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $159.25 | 2021-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $107.62 | 2021-2025 | |
| Astellas Pharma US INC | $56.88 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $54.20 | 2019-2024 | Airsupra |
| E.R. Squibb & Sons, L.L.C. | $45.27 | 2019-2021 | |
| C. R. Bard, INC. & Subsidiaries | $38.53 | 2024 | Bd Onclarity |
| Teva Pharmaceuticals USA, INC. | $37.84 | 2019-2021 | |
| Organon LLC | $30.44 | 2024 | |
| Tempus Ai, INC | $29.39 | 2024 | |
| Vanda Pharmaceuticals INC. | $28.48 | 2025 | Fanapt |
| Lilly USA, LLC | $24.66 | 2020-2023 | Mounjaro |
| Dexcom, INC. | $24.19 | 2024 | Dexcom G6 Transmitter |
| Corium, LLC | $23.49 | 2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $22.55 | 2020 | |
| Alfasigma USA, INC. | $22.18 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $19.42 | 2025 | Cologuard Collection Kit |
| Si-Bone, INC. | $19.38 | 2019 | |
| Amgen INC. | $18.56 | 2025 | Otezla, Repatha |
| Novo Nordisk INC | $17.72 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.48 | 2021 | |
| Allergan, INC. | $15.36 | 2019 | |
| Eisai INC. | $13.56 | 2021 | |
| Merck Sharp & Dohme LLC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Speer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.